Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 47Lymphoid 38Other hematologic neoplasm 22CNS 7Sarcoma 6Genitourinary 6Endocrine 5Plasma cell 3Dermatologic 3Other solid neoplasm 2NET 2Myeloid 2Head & Neck 2Gynecologic 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 2Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 13Specimen Handling 8Magnetic Resonance Spectroscopy 8Everolimus 8cabozantinib 6pembrolizumab 5Nivolumab 4olaparib 3lenvatinib 3X-Rays 3Lutetium-177 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2avelumab 2amino-acid, glucose, and electrolyte solution 2Sunitinib 2Radiotherapy 2Phantoms, Imaging 2Octreotide 2Ipilimumab 2Fluorodeoxyglucose F18 2Etoposide 2Cyclophosphamide 2Cisplatin 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2telotristat ethyl 1surufatinib 1repotrectinib 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Etoposide × NET × 90 days × Clear all
NCT06406465 2026-05-27

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
83 enrolled 13 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡